{
    "clinical_study": {
        "@rank": "119561", 
        "brief_summary": {
            "textblock": "RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing\n      so they stop growing or die. Combining more than one drug may kill more cancer cells.\n\n      PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating\n      patients who have acute B-lymphoblastic leukemia or recurrent non-Hodgkin's lymphoma."
        }, 
        "brief_title": "Combination Chemotherapy in Treating Patients With Acute B-Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma", 
        "completion_date": {
            "#text": "January 2003", 
            "@type": "Actual"
        }, 
        "condition": [
            "Leukemia", 
            "Lymphoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Lymphoid", 
                "Precursor Cell Lymphoblastic Leukemia-Lymphoma", 
                "Lymphoma", 
                "Lymphoma, Non-Hodgkin", 
                "Lymphoma, Large-Cell, Immunoblastic"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES: I. Improve the survival of children and adolescents with poor-risk\n      nonlymphoblastic lymphoma and acute B-lymphoblastic leukemia using an intensive,\n      short-course regimen of combination chemotherapy. II. Assess the toxicity of the regimen.\n\n      OUTLINE: Nonrandomized study. Induction: 7-Drug Combination Chemotherapy with Leucovorin\n      Rescue plus Triple Intrathecal Therapy (TIT). Cyclophosphamide, CTX, NSC-26271; Thiotepa,\n      TSPA, NSC-6396; Vincristine, VCR, NSC-67574; Daunorubicin, DNR, NSC-82151; Dexamethasone,\n      DM, NSC-34521; Etoposide, VP-16, NSC-141540; Methotrexate, MTX, NSC-740; with Leucovorin\n      calcium, Citrovorum Factor, CF, NSC-3590; plus TIT: IT MTX; IT Cytarabine, IT ARA-C,\n      NSC-63878; IT Hydrocortisone, IT HC, NSC-10483. Consolidation: 6-Drug Combination\n      Chemotherapy with Leucovorin Rescue plus TIT. ARA-C; VP-16; Asparaginase (E. coli), ASP,\n      NSC-109229; MTX; VCR; Methylprednisolone, MePRDL, NSC-19987; with CF; plus TIT. Reinduction:\n      7-Drug Combination Chemotherapy with Leucovorin Rescue plus TIT. CTX; TSPA; VCR; DNR; DM;\n      VP-16; MTX; with CF; plus TIT.\n\n      PROJECTED ACCRUAL: A maximum of 30 patients, accrued from 4 institutions, will be entered.\n      If at any time more than 3 patients are not \"event free\", the trial will be terminated\n      early, with patients considered event free if they enter remission, do not die as a result\n      of treatment toxicity, and do not experience progression within 1 year from the start of\n      therapy."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS: Newly diagnosed undifferentiated nonlymphoblastic non-Hodgkin's\n        lymphoma (Burkitt's or non-Burkitt's) Newly diagnosed large cell lymphoma with CNS\n        involvement Recurrent non-Hodgkin's lymphoma L-3 and B-cell leukemia included At least 1\n        of the following required: LDH at least 500 IU/liter (old method) or 2,000 IU/liter (new\n        method) Bone marrow involvement (greater than 5% lymphoblasts) CNS involvement\n        (lymphoblasts on CSF cytospin or intracranial mass on CT or MRI scan)\n\n        PATIENT CHARACTERISTICS: Age: Any age Performance status: Not specified Hematopoietic: Not\n        specified Hepatic: Not specified Renal: Not specified\n\n        PRIOR CONCURRENT THERAPY: Prior therapy allowed for non-Hodgkin's lymphoma No prior\n        therapy for all other diseases"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "firstreceived_date": "November 1, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002471", 
            "org_study_id": "90-013", 
            "secondary_id": [
                "CDR0000076672", 
                "NYU-97-9", 
                "NCI-V90-0104"
            ]
        }, 
        "intervention": [
            {
                "intervention_name": "asparaginase", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "cyclophosphamide", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "cytarabine", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "daunorubicin hydrochloride", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "dexamethasone", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "etoposide", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "leucovorin calcium", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "methotrexate", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "methylprednisolone", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "therapeutic hydrocortisone", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "thiotepa", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "vincristine sulfate", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Asparaginase", 
                "Cyclophosphamide", 
                "Cytarabine", 
                "Daunorubicin", 
                "Dexamethasone", 
                "Etoposide", 
                "Methotrexate", 
                "Methylprednisolone Hemisuccinate", 
                "Prednisolone", 
                "Thiotepa", 
                "Vincristine", 
                "Dexamethasone acetate", 
                "Cortisol succinate", 
                "Hydrocortisone acetate", 
                "Hydrocortisone 17-butyrate 21-propionate", 
                "Methylprednisolone acetate", 
                "Prednisolone acetate", 
                "Hydrocortisone", 
                "Methylprednisolone", 
                "Dexamethasone 21-phosphate", 
                "Prednisolone hemisuccinate", 
                "Prednisolone phosphate", 
                "BB 1101", 
                "Hydrocortisone-17-butyrate", 
                "Leucovorin", 
                "Levoleucovorin"
            ]
        }, 
        "keyword": [
            "childhood Burkitt lymphoma", 
            "L3 childhood acute lymphoblastic leukemia", 
            "B-cell childhood acute lymphoblastic leukemia", 
            "L3 adult acute lymphoblastic leukemia", 
            "B-cell adult acute lymphoblastic leukemia", 
            "recurrent adult non-Hodgkin lymphoma", 
            "stage III adult diffuse large cell lymphoma", 
            "stage III adult immunoblastic large cell lymphoma", 
            "stage III adult Burkitt lymphoma", 
            "stage IV grade 3 follicular lymphoma", 
            "stage IV adult diffuse large cell lymphoma", 
            "stage IV adult immunoblastic large cell lymphoma", 
            "stage IV adult Burkitt lymphoma", 
            "recurrent grade 3 follicular lymphoma", 
            "recurrent adult diffuse large cell lymphoma", 
            "recurrent adult immunoblastic large cell lymphoma", 
            "recurrent adult Burkitt lymphoma", 
            "stage III childhood small noncleaved cell lymphoma", 
            "stage IV childhood small noncleaved cell lymphoma", 
            "stage IV childhood large cell lymphoma", 
            "recurrent childhood small noncleaved cell lymphoma", 
            "recurrent childhood large cell lymphoma"
        ], 
        "lastchanged_date": "June 19, 2013", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/MSKCC-90013"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Ann Arbor", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48109-0752"
                    }, 
                    "name": "University of Michigan Comprehensive Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10016"
                    }, 
                    "name": "Kaplan Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10021"
                    }, 
                    "name": "Memorial Sloan-Kettering Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19104"
                    }, 
                    "name": "Children's Hospital of Philadelphia"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Phase II Trial of Intensive, Short-Course Combination Chemotherapy in the Treatment of Newly Diagnosed Patients With Poor-Risk Nonlymphoblastic Lymphoma and Acute B-Lymphoblastic Leukemia and in Patients With Recurrent Non-Hodgkin's Lymphoma", 
        "overall_official": {
            "affiliation": "Memorial Sloan-Kettering Cancer Center", 
            "last_name": "Norma Wollner, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2003", 
            "@type": "Actual"
        }, 
        "reference": {
            "citation": "Finlay JL, Wasserman R, Willoughby M, et al.: A pilot study of brief intensive chemotherapy for children with high-risk small non-cleaved cell lymphoma (SNCCL) and acute B-cell leukemmia (B-ALL). Med Pediatr Oncol 21(8): A-18, 535, 1993."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002471"
        }, 
        "source": "Memorial Sloan-Kettering Cancer Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Memorial Sloan-Kettering Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 1990", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }, 
    "geocoordinates": {
        "Children's Hospital of Philadelphia": "39.952 -75.164", 
        "Kaplan Cancer Center": "40.714 -74.006", 
        "Memorial Sloan-Kettering Cancer Center": "40.714 -74.006", 
        "University of Michigan Comprehensive Cancer Center": "42.281 -83.743"
    }
}